Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Lexicon announces data from LX4211 Phase 2b trial on type 2 diabetes

Lexicon Pharmaceuticals, Inc. announced that data from the Phase 2b clinical trial of LX4211 are being presented today as a Clinical Sciences Special Report in the Emerging Therapeutics for Diabetes and Dyslipidemia section of the American Heart Association (AHA) Scientific Sessions Conference held in Los Angeles, California.

7 Nov 2012

Low vitamin D levels mediate racial disparities in pain

A new study reveals that black Americans display lower levels of vitamin D and greater pain sensitivity compared to white Americans. Findings published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), indicate that vitamin D deficiency may be one of many factors that account for increased pain in older black Americans with knee osteoarthritis (OA).

7 Nov 2012

Testosterone exposure early in life can have lasting impact on brain function and behavior

New findings led by Dr. Michael Lombardo, Prof. Simon Baron-Cohen and colleagues at the University of Cambridge indicate that testosterone levels early in fetal development influence later sensitivity of brain regions related to reward processing and affect an individual's susceptibility to engage in behavior, that in extremes, are related to several neuropsychiatric conditions that asymmetrically affect one sex more than the other.

6 Nov 2012

Combination of mosquito nets and deltamethrin does not lead to decline in malaria

Some develop resistance. Others alter their behaviour. Mosquitoes of the genus Anopheles, the vectors of malaria, always find a way to foil human attempts to protect themselves from this disease. Researchers from the IRD and their partners have revealed their great capacity for adaptation, which weakens the strategies to combatting their presence, recommended by the WHO.

6 Nov 2012

Dysregulation of CISTR-ACT causes brachydactyly type E

The patients have single short fingers (metacarpals) and toes (metatarsals) and can be restricted in growth due to a shortened skeleton. This hereditary disease is called brachydactyly type E (Greek for short fingers).

6 Nov 2012

Gateway Aesthetic announces addition of three new procedures

The Gateway Aesthetic Institute & Laser Center in Salt Lake City, Utah is pleased to announce the addition of three new procedures to its broad list of available services in the aesthetics' arena.

5 Nov 2012

Neonatal TSH screening insensitive for iodine insufficiency

Measuring levels of neonatal thyroid-stimulating hormone may not be sufficiently sensitive for inferring the extent of iodine deficiency in a given population, study results suggest.

5 Nov 2012

Study highlights potential treatment that reduces kidney growth

Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications.

5 Nov 2012

Some types of bariatric surgery may cause bone loss, say endocrinologists

Bariatric surgery, which significantly curtails the amount of food a person can eat, is the most effective treatment against obesity and is being recognized as a potentially valuable tool in the fight against diabetes related to obesity.

3 Nov 2012

MED1 plays a central role in mediating tamoxifen resistance in breast cancer

A University of Cincinnati (UC) cancer biology team reports breakthrough findings about specific cellular mechanisms that may help overcome endocrine (hormone) therapy-resistance in patients with estrogen-positive breast cancers, combating a widespread problem in effective medical management of the disease.

3 Nov 2012

People's reactions to stressors determine health consequences, say Penn State researchers

Contrary to popular perception, stressors don't cause health problems -- it's people's reactions to the stressors that determine whether they will suffer health consequences, according to researchers at Penn State.

3 Nov 2012

Men with prostate cancer can benefit from active surveillance

With active surveillance many men with prostate cancer could dispense with radiation treatment and surgery, and thus avoid adverse effects such as incontinence and impotence. This is the outcome of a study of almost 1,000 men diagnosed with prostate cancer conducted at Sahlgrenska Academy, University of Gothenburg, Sweden.

3 Nov 2012

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

Bristol-Myers Squibb Company is pleased to announce that today the National Institute of Health and Clinical Excellence (NICE) has decided to recommend YERVOY (ipilimumab), which is approved in the European Union for the treatment of previously-treated metastatic (advanced) melanoma, within the Final Appraisal Determination (FAD).

3 Nov 2012

Scientists identify biomarker associated with tamoxifen resistance in women with breast cancer

Scientists have identified a molecular 'flag' in women with breast cancer who do not respond or have become resistant to the hormone drug tamoxifen.

From The University of Manchester 3 Nov 2012

Soy products do not prevent onset of vasomotor symptoms in women

A team of investigators led by UC Davis found that eating soy products such as soy milk and tofu did not prevent the onset of hot flashes and night sweats as women entered menopause.

2 Nov 2012

Takeda, Affymax announce data from OMONTYS Phase 3 studies on anemia due to CKD

Affymax, Inc. and Takeda Pharmaceuticals U.S.A., Inc. (TPUSA) today announced the presentation of post-hoc sub-group analyses of the EMERALD Phase 3 studies that evaluated OMONTYS (peginesatide) Injection, an erythropoiesis-stimulating agent (ESA), for the treatment of anemia due to chronic kidney disease (CKD) in adult dialysis patients.

2 Nov 2012